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Abstract
Background: The application of rehabilitation robots has grown during the last decade. While meta-analyses have
shown beneficial effects of robotic interventions for some patient groups, the evidence is less in others. We established
the Advanced Robotic Therapy Integrated Centers (ARTIC) network with the goal of advancing the science and clinical
practice of rehabilitation robotics. The investigators hope to exploit variations in practice to learn about current clinical
application and outcomes. The aim of this paper is to introduce the ARTIC network to the clinical and research
community, present the initial data set and its characteristics and compare the outcome data collected so far
with data from prior studies.
Methods: ARTIC is a pragmatic observational study of clinical care. The database includes patients with various
neurological and gait deficits who used the driven gait orthosis Lokomat® as part of their treatment. Patient
characteristics, diagnosis-specific information, and indicators of impairment severity are collected. Core clinical
assessments include the 10-Meter Walk Test and the Goal Attainment Scaling. Data from each Lokomat® training
session are automatically collected.
Results: At time of analysis, the database contained data collected from 595 patients (cerebral palsy: n = 208;
stroke: n = 129; spinal cord injury: n = 93; traumatic brain injury: n = 39; and various other diagnoses: n = 126). At
onset, average walking speeds were slow. The training intensity increased from the first to the final therapy
session and most patients achieved their goals.
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Conclusions: The characteristics of the patients matched epidemiological data for the target populations. When
patient characteristics differed from epidemiological data, this was mainly due to the selection criteria used to
assess eligibility for Lokomat® training. While patients included in randomized controlled interventional trials have
to fulfill many inclusion and exclusion criteria, the only selection criteria applying to patients in the ARTIC
database are those required for use of the Lokomat®. We suggest that the ARTIC network offers an opportunity
to investigate the clinical application and effectiveness of rehabilitation technologies for various diagnoses. Due to
the standardization of assessments and the use of a common technology, this network could serve as a basis for
researchers interested in specific interventional studies expanding beyond the Lokomat®.
Background
The number of technological devices that therapists can
utilize to treat people with neurological impairments has
grown substantially during the last decade. Alongside
this growth in clinical use, research involving robotic
therapy has grown rapidly. A search in Pubmed with
the terms “robot” OR “robotic*” AND “rehabilitation”
revealed 2225 hits (March 2017) with research markedly
increasing after 2010. Despite this increase in research
activity and clinical use, the effectiveness of robot-
assisted interventions in neurorehabilitation is still in
debate. While in some patient populations, for example
adults with stroke, meta-analyses have shown that
robotic interventions for the lower and upper extremity
can be beneficial [1, 2], current evidence is much less
convincing in other patient groups, such as spinal cord
injury (SCI), traumatic brain injury (TBI), multiple
sclerosis (MS) and cerebral palsy (CP).
When comparing the effectiveness of robot-assisted gait
training (RAGT) to conventional interventions of similar
dosage in adult patients after SCI, it appears that neither
intervention is superior [3, 4]. In other populations, such
as MS, a small number of pilot studies have been con-
ducted, and a review [5] concluded that the evidence for
the effectiveness remained inconclusive. In adult patients
with TBI, to our knowledge, there is only one randomized
controlled trial that investigated the effectiveness of
RAGT [6]. While RAGT improved gait symmetry com-
pared to manually assisted body-weight supported tread-
mill training, improvements in other gait parameters were
not different between the interventions. In children with
CP, the body of evidence is similarly small, as only two
randomized trials were found [7, 8]. To the authors’
knowledge, there are no randomized controlled trials in
children with other diagnoses. Studies comparing effect-
iveness between different patient groups are lacking.
One important factor leading to the lack of conclusive
research is the relatively small number of available
centers and participating patients and consequently the
small statistical power of attempted studies. Multicenter
collaborations are needed to achieve adequate number
of participants. Several of the limitations in the evidence
of the application of RAGT arise from patient
selection criteria and use of different, poorly described
and/or low-dosed training protocols. For example, when
systematically reviewing the literature in children, we
found no paper describing a training protocol on how to
apply a robot for rehabilitation of gait [9]. Most of the
systematic reviews mentioned that it is extremely
difficult to pool results from studies due to the large
variability in treatment duration and frequency, contents
of the training and inclusion criteria of the patients.
For children with CP, an expert team was created to
formulate goals, inclusion criteria, training parameters
and recommendations on including RAGT in the
clinical setting, to assist therapists who train children
with CP with the Lokomat® (Hocoma AG, Volketswil,
Switzerland) [9]. Such information could be used as a
first step in defining training protocols, but this infor-
mation is missing for most other patient groups.
While randomized controlled trials are usually consid-
ered the “gold standard” in building solid evidence in the
field of medicine, it is often difficult for rehabilitation spe-
cialists working in the clinical environment to interpret
the findings with respect to the population of patients they
treat on a daily basis. Randomized controlled trials require
a specialized team, a controlled setting and a strict selec-
tion of patients according to well defined inclusion and
exclusion criteria. These criteria often select individuals
most likely to benefit based on specific parameters
and lack of co-morbidities. These narrow criteria may
impact the ecological validity, as results only apply to
a minority of patients. This was recently investigated
by Dörenkamp et al. [10] who reported that the majority
of patients in primary care (40% at the age of 50 years and
at least two-thirds of the octogenarian population [11])
simultaneously suffered from multiple medical problems.
Further, improvements in function might be less compar-
able to results described in randomized controlled trials
and the treatment regimens used may not be applicable to
patients with multiple comorbidities.
To overcome these issues, we established the Advanced
Robotic Therapy Integrated Centers (ARTIC) network to
collect data from patients using RAGT in a wide variety
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of clinical settings. ARTIC hopes to develop guidelines
for usage as well as to answer scientific questions con-
cerning the use of RAGT. While the ARTIC network
includes a general patient population, other research
networks focus on a specific disorder or diagnostic
group (see, for example [12, 13]). ARTIC focuses on a
common technological intervention – currently the
driven gait orthosis Lokomat® – and aims to gather
evidence for the efficient and effective use of robotic
therapy. Variation in practice among ARTIC members
together with collection of common data and outcome
measurements will enable the group to draw strong,
generalizable conclusions. Further goals include estab-
lishing standardized treatment protocols and increasing
medical and governmental acceptance of robotic ther-
apy. The aims of this paper are to introduce the ARTIC
network to the clinical and research community,
present initial data on the characteristics of included
patients and compare these to those known from existing
epidemiological data and interventional studies.
Methods
The ARTIC network
ARTIC is an international group of diverse, clinically re-
nowned centers (Table 1) whose goal is to advance the
science of rehabilitation robotics. ARTIC includes clini-
cians who use the robotics and researchers who can
evaluate that usage and learn from the diversity of prac-
tice as well as patient populations. ARTIC receives tech-
nical and administrative support from a manufacturer.
ARTIC uses a prospective observational research design
referred to as practice-based evidence. Network mem-
bers treat different patient groups (Table 1) of different
ages in various in- or out-patient settings.
As an approach to begin this ambitious international
multicenter undertaking, it was essential to start with a
Table 1 Members of the ARTIC network
Institutions Patients / yeara Patient
diagnoses
Lokomat®
since
Other technologies
Spaulding, Boston, USA 50 SCI, CP,
stroke, TBI
2006 ArmeoSpring, ArmeoBoom, Erigo, FES bikes, ReWalk,
Ekso, Bioness H200, Bioness L300 plus
Shirley Ryan AbilityLabb, Chicago, USA 30 SCI, CP 2007 ArmeoSpring, Intelligent Stretcher
MossRehab, Philadelphia, USA 20 SCI, TBI,
stroke
2008 ArmeoSpring, ArmeoPower, Amadeo, Andago, Diego,
G-eo, Reo, ReWalks, Safe Gait, Pablo, Tibion, Tymo,
Sheltering Arms Physical Rehabilitation Center,
Richmond, USA
200 SCI, TBI,
stroke, MS
2011 Zero G, FES bikes, Bioness H200 and L300+, Balance
Master, Alter G Bionic Leg, ArmeoPower, SAEBO,
SAEBO MAS, Reo Go
Wellington Hospital, London, UK 30 SCI, TBI,
stroke
2011 ArmeoSpring, Erigo, Erigo Pro, FES bike, Bioness H200,
Indego
Tan Tock Seng Hospital Rehabilitation Centre,
Singapore, Republic of Singapore
20 SCI, TBI,
stroke, CP
2008 ArmeoSpring, ArmeoBoom, NeuroMove, Handtutor,
Jintronix Gaming platform, Dynavision, MIT Manus
(wrist robot), ReJoyce, SMART Balance Master
Schön Klinik, Vogtareuth, Germany 25 SCI, TBI,
stroke, CP
2006 ArmeoSpring, Biometrix, RehaMove
Von Haunersches Kinderspital München, München,
Germany
30 CP 2006 –
Rehaklinik Zihlschlacht, Center for Neurological
Rehabilitation, Zihlschlacht, Switzerland
40 SCI, stroke,
TBI,
Parkinson,
MS
2006 Erigo FES, Andago, ArmeoSpring, ArmeoPower,
ARMin, Bioness L300 Plus, Valedo, VICTOR and
EMMA, Tipstim
Rehabilitation Center for Children and Adolescents,
University Children’s Hospital Zurich, Affoltern am Albis,
Switzerland
35 SCI, CP,
stroke, TBI
2005 Andago, Amadeo, ArmeoSpring, ChARMin, Diego,
Erigo, Myro, YouGrabber
Rehabilitation Centre Kladruby, Kladruby,
Czech Republic
80 SCI, TBI,
Stroke
2009 ArmeoPower, ReoGo, Gloreha glove Professional,
Ekso, ErigoPro, Hand Tutor, FES bike, Balance Manager,
Balance master, Thera Trainer Balance, Postural
treadmill with dynamic weightless system
Seoul National University Bundang Hospital,
Seongnam, Republic of Korea
40 Stroke, TBI,
SCI
2015 ArmeoPower
University of Pittsburgh Medical Center,
Pittsburgh, USA
Currently consultant
Shepherd, Atlanta, USA Currently consultant
Abbreviations: SCI Spinal Cord Injury, CP Cerebral Palsy, TBI Traumatic Brain Injury, MS Multiple Sclerosis. aNumber of patients expected to be contributed to the database
annually; bpreviously known as Rehabilitation Institute of Chicago
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single common device, with the intention of learning
and expanding to other devices. At initial meetings,
ARTIC members discussed multiple rehabilitation ro-
botic devices and decided to go with the Lokomat® be-
cause it was the most widely used device with, at that
time, over 550 worldwide devices in use since its market
introduction in 2000 [14] and all but one of the founding
centers had active clinical programs using the Lokomat®.
Careful mechanisms were put in place to assure
scientific independence from the industrial partner.
For example, ARTIC members elect the leadership
independently, and the ARTIC database is located at
an independent medical center (Boston) and governed by
that center’s human subject regulations.
The centers communicate with each other on a regular
basis. We have monthly phone and internet conferences
for the therapists, who update each other on new devel-
opments, discuss issues with the database or propose
solutions for improving the clinical application of the
Lokomat®. The principal investigators of each center
have at least quarterly calls and meet in person once a
year. Criteria to become part of the network are: at
least one person who speaks English, site-specific IRB
approval, able to join the web/phone conferences, able
to contribute at least 20 complete datasets per year
(definition see paragraph “Database”), therapists with ad-
vanced training in technology application, and suffi-
cient expertise in applying the robotic system (i.e.
more than 700 h of Lokomat® training).
Common technological intervention: The Lokomat®
The Lokomat® exoskeleton system comprises a treadmill
belt, a weight support system and a driven gait orthosis
for both legs (Fig. 1). Depending on the size of the
patient, there are pediatric leg orthoses for children with
a femur length between 21 and 35 cm, or adult leg
orthoses intended for patients with a femur length
between 35 and 47 cm. The patient is secured with three
cuffs per leg to the orthosis. The hip and knee joint of
the device are actuated. The robotic control uses an ad-
justable (impedance) controller with adjustable pre-
defined trajectories for hip and knee joints. Elastic straps
provide dorsiflexion assistance to the feet. The Lokomat®
system can be adjusted to get the best possible fit for
each patient. Therapists can use games providing bio-
feedback for increasing patients’ motivation (see e.g. [15,
16]). Recent developments include a FreeD mode (move-
able pelvis and leg cuffs), new control mechanisms (i.e.
path control rather than position control) and innovative
virtual scenarios.
Inclusion criteria for Lokomat® training are a femur
length of at least 21 cm (pediatric Lokomat®) or 35 cm
(adult Lokomat®), a bodyweight ≤135 kg, and being able
to signal pain, fear or discomfort reliably. Patients
unable to use the Lokomat® are those who have
severe lower extremity contractures, fractures, osseous
instabilities, osteoporosis, severe leg length discrepancy,
unhealed skin lesions, acute thrombo-embolic disease,
cardiovascular instability, mechanical ventilation, severe
cognitive deficits, or aggressive and self-harming behavior.
Database
One core component of the network was the development
of the online database. The international multicenter
approach of this project ensures the ascertainment of
a sufficient number of cases with a broad spectrum
Fig. 1 Lokomat® system (of different generations) with (a) adult leg orthoses and (b) pediatric leg orthoses. Patients walk on a treadmill belt, are
weight supported, and the exoskeleton device guides the legs through a physiological walking pattern
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of neurological and functional deficits. For each
patient, gender, age, and date of the lesion (for
acquired lesions) are recorded along with diagnosis-
specific indicators of the severity and basic characte-
ristics of the disorder (Fig. 2). For example, while for
patients with SCI the ASIA Impairment Scale (AIS)
and neurological level of lesion are assessed [17], the
classification according to Bax [18] and the Gross
Motor Function Classification System (GMFCS) are
collected for children with CP [19].
The selected assessments cover several domains ac-
cording to the International Classification of Functioning,
Disability, and Health (ICF; e.g. body functions, activities,
participation). We strived for a good balance between the
time and effort required and the amount of collected
information, as the goal was to have centers implement
ARTIC activities into clinical routines with existing
clinical personnel and resources.
The core clinical assessment set consists of the 10-
Meter Walk Test (10MWT) and the Goal Attainment
Scaling (GAS). The 10MWT was originally developed to
measure walking capacity in patients with stroke [20] and
was shown to be valid and reliable in a mixed group of
neurological patients [21]. Its psychometric properties
have been well investigated in adult patients with in-
complete spinal cord injury showing good reliability
and excellent responsiveness [22, 23]. In these patients,
walking speed could also predict functional walking
performance well [24]. In adult patients with stroke, the
10MWT proved sensitive to change (although the 5-m
walk test was slightly better) [25]. In children with
neurological gait disorders, the 10MWT showed good
reliability [26].
The GAS is an example of an individualized evaluative
instrument, which is used for measurement of changes
in individual patients and groups of patients based on
self-selected goals. Originally, a 5-point scale was devel-
oped by Kiresuk and Sherman [27], but we are using the
more recent 6-point scale according to Steenbeek et al.
[28]. The following scores apply: − 3, worse than start; −
2, equal to start; − 1, less than expected; 0, expected
goal; + 1, somewhat more than expected, and + 2, much
more than expected. The GAS proved applicable to pa-
tients with acquired brain lesions [29]. In pediatric re-
habilitation, the GAS has been shown to be reliable, as
the scales constructed by the children’s therapists had an
inter-rater reliability of .82 (95% confidence interval
.73–.91) [30], and the sensitivity to change proved to be
good (for a review article see [31]). Also for adult pa-
tients, a review supported the validity, reliability and
sensitivity of goal setting [32]. In the ARTIC database,
there is an option to indicate whether the defined goals
reflect an aspect of gait speed, endurance, or quality or
other gait-related aspects.
Additional assessments that can be recorded in the
database include the Modified Ashworth Scale (MAS),
which is commonly used as an ordinal measure of spas-
ticity [33] and the Medical Research Council Scale
muscle strength score, which is commonly used and reli-
able [34]. Muscle strength is scored between 0 (total par-
alysis) to 5 (normal; active movement, full range of
motion against gravity, and full resistance in a functional
Fig. 2 ARTIC Database containing information on patient demographics, diagnosis and severity, assessments and training parameters. Training parameters
are stored for each separate training session to enable an evaluation over time. The 10-Meter Walk Test and the Goal Attainment Scaling
are two core clinical assessments
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muscle position expected from an otherwise unimpaired
person). Centers that use the Functional Independ-
ence Measure (FIM) [35] or the Functional Independ-
ence Measure for children (WeeFIM) [36] also enter
these in the database.
Besides clinical and functional information, data from
each Lokomat® session are automatically collected and
can subsequently be integrated into the database (Fig. 2).
This study concept allows for a detailed evaluation of
training intensity, frequency, and parameters in com-
parison to therapy progress and outcome taking into
account a basic characterization of the neurological
condition of each patient.
In this paper, we used only descriptive analyses.
Results
Data collection started in January 2014. Several cen-
ters joined later (e.g. Vogtareuth, Munich, Wellington,
Prague, Bundang). The number of patients entered
into the ARTIC database by May 2016 was 595. The
four largest groups based on diagnoses were CP,
stroke, SCI, and TBI. Another large group, “others”,
included patients with various other neurological diag-
noses, such as Guillain-Barré syndrome, brain tumors,
encephalitis, transverse myelitis, myelomeningocele,
and others (Fig. 3).
To provide insight into the type of patients receiving
Lokomat® therapy, we have presented more details of the
largest patient groups. While the distribution of gender
was relatively similar for patients with CP (females 45%)
and stroke (females 46%), we found more males in
patients with SCI (72%) and TBI (77%). Furthermore,
the distribution of age was different between the groups
(Fig. 4). Patients with CP were mainly under the age of
20. For patients with SCI the age showed a close-to-normal
distribution, although we observed some peaks between
21 and 30 and 51–60 years. While patients with stroke
showed a skewed distribution to the right, with a peak
between 60 and 70 years, patients with TBI showed a
skewed distribution to the left with a peak between 11
and 20 years.
We also evaluated the time from injury to starting
their first Lokomat® training (Table 2). Almost 30% of
the patients started their training within the first month
post event.
Concerning clinical characteristics (Fig. 3), the largest
number of patients with CP had a spastic bilateral CP
and a GMFCS level III or IV. A small majority of the
patients with stroke had experienced an ischemic rather
than a hemorrhagic lesion. The lesion of patients with
SCI was predominantly of traumatic origin (72%), had
resulted in most patients in an AIS C, and the neuro-
logical level of lesion was most frequently diagnosed at
cervical 4 (Fig. 3).
As we plan detailed analyses on the amount of training
for future studies, we refrained from any statistical
analyses in the current paper. Initial results show that in
general the intensity of training seems to increase (i.e.
longer training duration, larger distances covered, higher
walking velocities and less supportive force from the
Lokomat®) from the first to the final Lokomat® training
session (Table 3).
Finally, we show initial results of the 10MWT performed
at onset of the Lokomat® intervention (Fig. 5). The
time needed to walk 10 m is considerable and seems
to be longer for patients with higher severity grades.
Despite poor initial walking function, many patients
achieve their goals, as indicated by the GAS. In general,
only single patients deteriorate (GAS score − 3), some
remain at their initial level (GAS score − 2), and several
improve, but less than expected (GAS score − 1). Most
patients seem to achieve their goal (GAS score 1) or
somewhat (GAS score + 1) or even much more (GAS
score + 2) than expected. The percentages of patients
that achieve their goal (encircled in blue. Figure 5)
amounts to 69% (CP), 74% (stroke), 56% (SCI) and
83% (TBI).
Discussion
The ARTIC network was successful at getting a number
of centers to contribute data without the need for a
financial incentive. The network was able to amass a
relatively large dataset in a relatively short time. The
data collected included subject characteristics, outcomes,
and training information.
We addressed the first two aims of this paper, to
introduce the ARTIC network to the clinical and
research community and present first data on the
characteristics of included patients, in the previous
paragraphs. We will discuss below the characteristics
of the patients included in the ARTIC database by
comparing them with those published in epidemio-
logical and interventional studies, in line with the
third aim of this study.
Cerebral palsy
Compared to epidemiological studies, the ARTIC data-
base contains an overrepresentation of children with
bilateral spastic CP (86%) and an underrepresentation of
children with unilateral spastic CP (4%). The proportion
of children with bilateral spastic CP varies between
countries (e.g. Denmark 51% and Norway 43%, [37]).
Spastic bilateral CP was found in 45.7% of the 3′948
children from 14 Surveillance of Cerebral Palsy in
Europe (SCPE) registers in Europe [38] and in 49.2%
of the 451 children with CP from the Autism and
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Developmental Disabilities Monitoring (ADDM) Network
in four areas in the USA [39]. The proportion of children
with unilateral spastic CP varies between 28.2% and
40% (Denmark: 37%, Norway: 40%, [37]; SCPE: 39.2%,
[38]; ADDM Network: 28.2%, [39]. In general, children
with an ataxic or dyskinetic (dystonic or chorea-athethotic)
CP are relatively rare (e.g. [37–39]), and this is in line with
the small numbers in our database.
The ARTIC database shows an overrepresentation
of children with GMFCS levels III and IV (each 39%,
Fig. 3 Clinical characteristics of the patients. (a) The largest group of patients are those with a Cerebral Palsy (CP), followed by stroke, spinal cord
injury (SCI) and traumatic brain injury (TBI). (b) The clinical diagnosis according to Bax and (c) the severity grade according to the Gross Motor Function
Classification System (GMFCS) are shown for patients with CP. (d) For patients with stroke, the distribution between patients with ischemic
versus hemorrhagic stroke is shown. (e) For patients with SCI, the ASIA Impairment Scale (AIS) is shown and reflects the severity (AIS A, sensorimotor
complete; AIS B motor complete, sensory incomplete; AIS C and D sensorimotor incomplete with AIS C indicating that less than half of the muscles
below the neurological level of lesion have a muscle grade of 3 or more and AIS D indicating that half or more of the muscles below the neurological
level of lesion have a grade 3 or higher). (f) Finally, the distribution of the neurological level of lesion is presented. Abbreviations: C, cervical; T, thoracic;
L, lumbar and S, Sacral
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see Fig. 3) compared to epidemiological numbers.
Christensen et al. [39] reported that GMFCS levels III
and IV accounted for 12.3% and 16.8%, respectively.
In children with bilateral spastic CP, these percent-
ages were higher and amounted to 15.3% (level III)
and 21.2% (level IV). They further mention that
‘nearly all children with unilateral spastic CP walked
independently (96.6%) compared with less than half
of those with bilateral spastic CP’ (45.4%). The cause
of the ‘overrepresentation’ of children with a bilateral
spastic CP with GMFCS levels III and IV in the
ARTIC database is most likely due to the clinical
reasoning underlying the selection of patients treated
with the Lokomat®. Their walking ability is moderate
to severely affected, but still, the goal is to achieve a
certain level of walking, which would exclude chil-
dren with GMFCS level V.
The authors are aware of only two published ran-
domized controlled Lokomat® trials in children with CP.
Druzbicki et al. [7] aimed at investigating changes in
temporospatial and kinematic gait parameters in chil-
dren with spastic diplegia. The children were between
6 and 13 years old, had spastic diplegia, the ability to
independently stand and walk or walk with assistance,
and a GMFCS level II or III. They excluded children
with disorders of higher mental functions, Lokomat®
related exclusion criteria, and those who were treated
with botulinum toxin during the last 6 months and
treated surgically within the past year. While the
participants should perform 20 sessions a 45 min, the
actual training dosage was not reported. Wallard et al.
[8] investigated the effect of Lokomat® training on the
dynamic equilibrium control during walking. They
included 30 children with bilateral spastic CP and
jump gait, GMFCS level II, aged 8 to 10 years, and the
ability to independently stand and walk or walk with
assistance (e.g. walking stick). They should perform 20
sessions (maximally 40 min of walking time), but did
not report the actual training dosage. It seems that the
patients in the Wallard et al. [8] study were less
severely affected compared to the patients in the
ARTIC database, as their children would need on
average about 11.8 s to complete the 10MWT (initial
walking speed of 0.85 m/s). While also the patients in
Fig. 4 Histograms showing the distribution of age for patients with Cerebral Palsy (CP), stroke, spinal cord injury (SCI), and traumatic brain injury
(TBI). Please note the different scales on the y-axes. Grey lines indicate distributions of age, which are based on numbers from the following
epidemiological studies: stroke [40], SCI [53], and TBI [61]
Table 2 Time between lesion and first Lokomat® training
Patient groups Proportion of patients [%]
0–1 month 1–3 months 3–6 months 6–12 months > 12 months
Stroke (n = 71) 28% 30% 15% 8% 18%
SCI (n = 92) 29% 18% 15% 10% 27%
TBI (n = 28) 29% 14% 29% 7% 21%
Abbreviations: SCI spinal cord injury, TBI traumatic brain injury. Number of missing observations: stroke, n = 61; SCI, n = 2; TBI, n = 11
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the study by Druzbicki et al. [7] seem at first sight less
affected (e.g. GMFCS levels II and III), these patients
would have needed on average about 29 s to perform
a 10MWT (initial walking speed of 0.35 m/s.), which
is more than the average GMFCS level III patients
would need in the ARTIC (see Fig. 5).
Due to these differences, it remains difficult to
estimate to what extent the results from such inter-
ventional studies can be generalized to the patients
who receive their Lokomat® training clinically.
Stroke
The Global Burden of Diseases, Injuries, and Risk
Factors (GBD 2013) study presented an update on the
global burden (data from 188 countries) of ischemic
and hemorrhagic stroke between 1990 and 2013 [40].
If we compare the patients’ characteristics of the
ARTIC database with the 2013 numbers from developed
countries from that paper, we see an overrepresentation
of patients with hemorrhagic stroke in the ARTIC data-
base (43% ARTIC versus around 20% worldwide). This
might be explained by the finding that patients with a
hemorrhagic stroke are often more severely affected
than patients with ischemic stroke. Furthermore, the
number of children with stroke is overrepresented in
the ARTIC database (Fig. 4), which can be explained
with the relatively high number of participating tertiary
pediatric rehabilitation centers in our network. While
we observe a peak in patients aged 60 to 70 years old
(Fig. 4), the worldwide incidence and prevalence of
patients after stroke is higher in patients aged 70 years
and older [40]. A discussion of this difference is specu-
lative, but we suggest that patients of higher age, with
multiple co-morbidities and poorer general health con-
dition, will be less frequently referred for robot-assisted
training or are cared for in nursing homes. The equal
distribution of females versus males in our database is
in line with the gender distribution worldwide [41] or
hospitalization rates in the USA [42].
Many randomized controlled trials with the Lokomat®
have been performed in patients with stroke (e.g.
[43–50]). Results from these studies have been summarized
in systematic reviews (e.g. [2, 51]) and recommendations
have been made in national treatment guidelines (e.g. [52]).
Only general observations can be made at this time
comparing available data.
Most studies included patients within the first year
after stroke, except for, for example, Kelley et al. [46]
and Bang and Shin [43] who also included chronic
patients. The time after lesion should be taken into
consideration, as in subacute patients spontaneous
neurological recovery might also contribute to the observed
functional improvements.
All studies included only patients with a first-ever
stroke and most studies excluded patients with accom-
panying orthopedic or neurological diagnoses or multiple
medical problems. While most Lokomat® sessions lasted
around 45 min, the number of sessions varied between
these trials: 12 [50], 15 or 30 [47], 16 [49], 18 [48],
20 [43, 45], 24 [44] or 40 [46]. As the average age
was around 50 years old (e.g. [49]) or older, it is
likely that many patients had to be excluded due to
co-morbidities. This is in line with the practical observa-
tion that patient recruitment in the field of stroke research
for randomized studies takes time. Therapists working
with the Lokomat® should therefore not be disappointed
when progress in gait training in their patients with
stroke is less as reported in randomized trials, as
these patients might differ on several aspects relevant
for relearning to walk.
Spinal cord injury
The National SCI Statistical Center estimates that the
annual incidence of SCI in the US approximates 54 cases
Table 3 Training parameters (mean ± standard deviation) at onset and end of Lokomat® training period
Patients Duration walking time
per session [min]
Distance walked per
session [m]
Average walking speed
[km/h]
Guidance Force [%]a Number of
training
sessionsGMFCS Onset End Onset End Onset End Onset End
Cerebral Palsy II 24.7 ± 9.3 31.6 ± 10.7 555 ± 282 918 ± 320 1.12 ± 0.53 1.45 ± 0.63 85.1 ± 14.5 69.4 ± 20.4 27.2 ± 28.8
III 23.4 ± 12.2 33.3 ± 11.6 524 ± 355 917 ± 401 1.13 ± 0.51 1.41 ± 0.59 83.1 ± 17.4 73.1 ± 18.8 23.4 ± 17.2
IV 24.2 ± 9.9 33.9 ± 10.3 522 ± 295 980 ± 373 1.25 ± 0.38 1.68 ± 0.42 84.3 ± 14.6 74.6 ± 16.0 21.8 ± 13.7
Stroke Ischemic 16.7 ± 9.0 29.3 ± 10.7 409 ± 258 886 ± 372 1.14 ± 0.57 1.42 ± 0.66 92.9 ± 16.4 85.4 ± 16.4 16.2 ± 14.5
Hemorrhagic 16.1 ± 6.8 29.3 ± 9.9 386 ± 198 858 ± 374 1.05 ± 0.60 1.26 ± 0.64 90.0 ± 23.4 81.4 ± 19.5 17.9 ± 17.9
Spinal cord injury AIS C 16.7 ± 6.6 24.0 ± 9.5 423 ± 247 759 ± 368 1.65 ± 0.44 1.88 ± 0.50 98.1 ± 5.0 84.2 ± 19.6 10.3 ± 14.8
AIS D 19.1 ± 3.1 22.2 ± 4.5 536 ± 124 700 ± 113 1.55 ± 0.52 1.77 ± 0.58 98.0 ± 2.7 92.2 ± 10.3 30.5 ± 60.3
Traumatic brain injury 15.4 ± 7.7 21.8 ± 13.6 350 ± 162 624 ± 428 1.14 ± 0.68 1.37 ± 0.73 85.0 ± 22.4 79.3 ± 22.5 24.1 ± 29.4
Abbreviations: GMFCS Gross Motor Function Classification System, AIS ASIA Impairment Scale. aPresented for left leg
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per million inhabitants [53]. The average age is currently
42 years (distribution of age at onset is shown in Fig. 4),
and about 80% of the new cases are males. Both
numbers are more or less in line with those reported
in our data. At onset of rehabilitation, the distribution
of the AIS was according to the National SCI Statistical
Center: AIS A, 40.5%; AIS B, 12.2%; AIS C, 18.2%; AIS D,
29.0% and AIS E, 0.0% (data from 4′452 patients).
We have considerably fewer patients in ARTIC with
AIS A and considerably more with AIS C. One simple
explanation is that most patients with AIS A do not
have the goal of achieving independent walking and,
Fig. 5 Clinical outcome measures. On the left are the average and SD times (in seconds) presented that the patients need to walk 10 m at onset
of Lokomat® training. For some patient groups, results are separated according to severity grades (e.g. the Gross Motor Function Classification Systems
levels I, II, III or IV for patients with CP or the ASIA Impairment Scales C and D for patients with spinal cord injury) or etiology of stroke (ischemic versus
hemorrhagic). Displayed at the right are the Goal Attainment Scores. Despite poor initial walking function, many patients achieved their goals
(Goal Attainment Scores 0, 1 or 2; encircled in blue)
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therefore, do not receive Lokomat® training. Patients
with AIS C are severely impaired in gait, but have
potential to improve and can therefore be considered
a target group for Lokomat® therapy. While the National
SCI Statistical Center reports level of lesion only at
discharge, the distribution of the neurological level of
lesion is well comparable to ours (Fig. 3f ).
Various randomized controlled Lokomat® studies in
patients with SCI have also been published. A recent
systematic review reported studies on pediatric and adult
patients with SCI [54]. Several randomized Lokomat®
studies have been performed in patients with SCI
showing that also in these patients the number of
studies is growing steadily [55–60]. In these studies, the
(average) number of training sessions varied considerably:
16 [58], 34 [60], around 40 [55, 56, 59] or even 60 [57].
When comparing the characteristics of the patients in
the ARTIC database with the patients in these studies,
most studies included patients with AIS C or D. None
included patients with AIS A and only some (e.g. [60])
included patients with AIS B. Some patients in the
ARTIC database are diagnosed as AIS A or B. At first
sight, it might not make clinical sense to include patients
with a motor complete lesion (AIS A and B) in a driven
gait orthosis to improve walking, but one should also
think of the level of lesion that could play a role. While
most studies excluded patients with signs of lower motor
neuron lesions, one study investigated differences
between patients with upper versus lower motor neuron
lesions specifically [56]. Looking at the level of lesion of
most patients in the ARTIC database, there will be only
a few patients with lower motor neuron lesions undergo-
ing Lokomat® training. Most studies included patients
with both traumatic and stable non-traumatic lesions
and this is in line with the patients, which receive
Lokomat® training in the ARTIC network. In line with
the previous discussion on age and multiple medical
issues, the average age of the patients with SCI was in
most studies between 40 and 50 years (e.g. [55–57]),
while it exceeded 50 years in other studies (e.g. [58, 59]).
In the ARTIC database, 43% of the patients with SCI are
50 years or older. As most randomized studies reported
that patients should have no other neurological, ortho-
pedic or cardiovascular issues, we can assume that also
for these studies inclusion and exclusion criteria resulted
in a particular patient population that might not entirely
resemble the patients with SCI that receive Lokomat®
therapy in a clinical setting.
Traumatic brain injury
According to the Traumatic Brain Injury Model System
(TBIMS) [61], the distribution of gender of patients with
TBI who received inpatient rehabilitation in the USA
between 1989 and 2015 was 26% females and 74% males
(similar number for 2016). These numbers are com-
parable to our data (23% females and 77% males). The
average age of patients with TBI in the TBIMS database
is 41.4 years (n = 14′624), which appears older compared
to the age of the patients with TBI included in our data.
This is likely caused by differences in the inclusion
criteria, as patients should be 16 years or older to be
included in the TBIMS database, while we also include(d)
younger children and adolescents. According to the
Centers for Disease Control and Prevention (CDC),
those most likely to sustain a TBI are children aged 0
to 4 years, older adolescents aged 15 to 19 years, and
adults aged 65 years and older [62]. While our data also
show the highest peak in adolescents aged 10–20 years,
we find no peak in children below 10 years. We can
easily explain this lack of agreement by differences in
epidemiology (0–4 years) versus Lokomat® training
inclusion criteria (older than 4 to 5 years). Unlike
epidemiological data, we find no peak in patients aged
65 years and older. Perhaps similar to our suggestion
for the elderly patients with stroke, physicians might
refer these patients less frequently for robot-assisted
training due to the higher age, multiple co-morbidities
and poorer general health condition.
To our knowledge, literature on the use of the
Lokomat® in patients with TBI is rare and we are
familiar with only one randomized controlled trial [6].
The chronic patients aged 18 years or older partici-
pated in 18 sessions and walked at onset on average
with a speed of around 0.37 m/s (estimated from the
figure). As this corresponds to about 27 s for the
10MWT, these patients seem better compared to the
patients with TBI in ARTIC who needed almost 70 s to
complete the 10MWT (Fig. 5). Importantly, the ARTIC
database uses few characteristics to describe the patients
with TBI. This is a limitation that should be resolved if we
intend to improve our knowledge on the applicability
of Lokomat® training for this patient group.
In summary, these paragraphs show that the character-
istics of the patients included in ARTIC fitted in general
with epidemiological data. We can explain certain devia-
tions from epidemiological numbers due to particular
patient selection for undergoing Lokomat® training
and the high number of participating pediatric centers.
Furthermore, while patients included in randomized
controlled interventional trials have to fulfill many
inclusion and exclusion criteria, the only selection
criteria applying to patients in the ARTIC database
are those related to the use of the Lokomat®, which
make it difficult to generalize findings from randomized
trials to patients treated on a daily basis.
In the introduction, we mentioned that such narrow
in- and exclusion criteria of interventional studies might
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limit the ecological validity, as results only apply to a
select subgroup of patients. While this could allow for
better targeting of specific treatments to specific
patients, it limits its generalization. Improving our
knowledge of biomarkers that could differentiate
between responders and non-responders, is an important
area of research. For example, in a recent publication,
participants from the Stroke Recovery and Rehabilitation
Roundtable published a paper in which they made recom-
mendations on when and where to include biomarkers
derived from imaging or neurophysiological techniques
for advancing practice and research [63]. While we agree
that rehabilitation in the future could be more effective
for patients identified as responders, it should be noted
that ‘ready for use’ stroke biomarkers are currently lacking
for most functional domains [63]. Furthermore, it remains
unanswered how therapists should treat ‘non-responding’
patients in their daily practice. Likely, therapists will apply
task-specific, repetitive, intensive exercises focusing on
improving major impairments and limitations of the
individual patient. These patients might show less or
slower progress compared to patients identified as
responders. Our network aims to contribute to these
developments, as we might identify patients who might
respond better to RAGT or recognize characteristics of
interventions that prove more effective than others.
Training dosage and parameters
While the number of training sessions varied between
the randomized trials that we reported, they vary consid-
erably in our database, as indicated by the large standard
deviations. For children with CP, the average number of
training sessions in ARTIC slightly exceeds those re-
ported in the clinical trials (n = 20). The average number
of sessions for patients with stroke (16 to 18 sessions)
seems in line with the majority of the randomized trials
that we referenced to and is in general relatively low. It
is possible that natural recovery and increased respon-
siveness leads to shorter duration of Lokomat® training.
For patients with SCI, we notice a low mean number of
sessions (n = 10) for patients with AIS C and around 30
sessions for patients with AIS D. Despite that we would
consider patients with AIS C a typical target group for
Lokomat® training, it is possible that lack of rapid gains
in these patients led to less training or that these
patients might have changed to over-ground training
conditions as soon as they could bear weight and initiate
stepping movements. Finally, patients with TBI in ARTIC
receive on average slightly more sessions (n = 24)
compared to patients who participated in the (only)
randomized trial (n = 18). While the number of sessions is
an important measure for future analysis on dosage-
response relationships, discussions on its differences
between randomized studies and ARTIC or between
patient groups are limited by practical issues such as
insurance companies who might finance only a specific
number of sessions, irrespective of severity of limitations.
Interestingly, most randomized studies do not report
detailed information on training dosage and parameters
(one positive exception is e.g. [60]). Most studies stated
that x sessions of y minutes of training with the Lokomat®
or control intervention were performed. They lack an
accurate listing of the actually achieved number of train-
ing sessions, pure training times, and training parameters
such as exact duration of walking, walking speed or
guidance force. Such information is valuable, as it
would allow in combination with functional outcome
measures to estimate the dosage needed to achieve a
particular functional improvement and make recom-
mendations for training protocols. For future studies, it
would be of interest that authors report the interventions
into more detail. Authors could adhere to the recommen-
dations formulated in the Template for Intervention
Description and Replication (TIDieR) checklist [64]).
When looking at Table 2, it seems that especially the
walking duration, the distance walked, and the average
walking speed increase considerably during the training
sessions. While we assume that this is due to the
improved ability of the patient to participate in training,
the Lokomat® parameters could be influenced by other
issues we cannot fully determine from the data.
Compared to the other parameters, the guidance
force seems to change less from onset to end.
Guidance force can be adjusted from 100% (this is
impedance control, which corresponds to a position-
controlled mode) to 0%. At 0% the Lokomat® will
not provide support for the patient’s movements and
should only compensate for robotic dynamics
(gravity and Coriolis forces) but not for inertia (for
an overview see [65]). At 100% guidance, no
deviation is possible from a predetermined move-
ment trajectory for the hip and knee joints and, the-
oretically, patients do not need to participate
actively. In healthy participants, walking under 100%
guidance force generally reduces muscle activity, but
even then, muscles show phased activity, indicating
that participants still actively controlled the gait
movements [66]. In children with neuromotor
disorders, walking under 100% guidance force results
in a more physiological activation of leg muscles
compared to unassisted treadmill walking [67] or to
Lokomat® training with other control strategies that
allow more variability [65]. We might therefore
assume that therapists prioritize a physiological
walking pattern and rather adjust parameters like
duration or speed to increase the intensity of the
training, while maintaining a physiological pattern.
van Hedel et al. Journal of NeuroEngineering and Rehabilitation  (2018) 15:30 Page 12 of 16
However, more detailed analyses including additional
parameters and multiple time points during the training
program are needed to verify this assumption.
Creating the database – Lessons learned
Many factors led to the success of bringing these data
together. Foremost was leadership and support of the
company. While no sites were paid to enter data,
many processes were put in place to make this as
easy as possible. In addition, the company supported
meetings and produced the minutes. The company
did not have a vote on critical decisions made by the
network nor on the contents of the ARTIC network’s
scientific output. This effort represents an example of
industry clinical partnership that has the ability to
benefit the clinical and research community.
Another critical factor was a steady and concerted
effort to not make data collection onerous. While
researchers desire in general to collect more data,
clinical partners might stop participating if data
collection might require too much time. It is clearly a
tradeoff, as more data would allow analyses that are
more detailed. The ARTIC network hopes they struck
the right balance, and while initial results seem
positive, further analyses are needed.
Finally, this work was made possible through numerous
people at each site who believed in the effort and
volunteered their time.
Limitations
Like most networks, it takes considerable time not
only to increase the numbers but also to improve the
quality of the data (e.g. completeness, standardization,
accurate reporting). We, therefore, maintain a con-
tinuous effort to train personnel and improve the
database content. Nevertheless, we initially had miss-
ing data. Furthermore, from time to time, we updated
the database. New, more detailed, data can be col-
lected but is missing for those patients who received
their Lokomat® training during an earlier phase. We,
therefore, presented in this study only data of patient
groups that are more complete. We will perform
future evaluations for specific patient groups to get
information that is more detailed in terms of patient
criteria, changes in training parameters and functional
progress, and goal attainment.
Concerning goal attainment, it is promising that most
patients achieved their goals, but we need to consider
that many patients also received additional conventional
interventions besides Lokomat® therapy.
Furthermore, due to the pragmatic nature of this data
collection effort, all patients undergo Lokomat® training
and we do not have a control group. Also, we will not be
able to collect data in similar detail as, for example,
randomized controlled clinical trials. This has, of
course, its limitations concerning our research ques-
tions. Nevertheless, if additional outcomes are desired,
the network provides an excellent basis to start such a
project. Experienced assessors already assess many
measures in a standardized way, and we could add
additional project specific outcomes if financial resources
are available.
Conclusions
As the degree of performance improvement depends on
the amount of practice, rehabilitation robots have the
potential to provide such intensive therapies. Importantly,
the ARTIC network assesses the application and changes
in function, activities and patient-relevant tasks in the real
neurorehabilitative environment. While patients included
in randomized controlled interventional trials have to
fulfill many inclusion and exclusion criteria, the only
selection criteria applying to patients in the ARTIC
database are those related to the use of the Lokomat®.
Indeed, while some patient characteristics differed from
epidemiological data, mainly due to particular patient
selection for undergoing Lokomat® training, most charac-
teristics fitted with epidemiological data.
This network offers a unique opportunity to investi-
gate the implementation, application, and effectiveness
of rehabilitation technologies. Within the network,
clinical practice and research are strongly inter-
connected. There is a continuous exchange of knowledge
and expertise between researchers and therapists. The
network offers the opportunity to develop standardized
protocols and guidelines for the application of robotic
technologies. Such guidelines could achieve strong
international acceptance as experienced rehabilitation
specialists working in internationally renowned centers
develop them.
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